Sequenta Earns CLIA Certification  
10/24/2012 9:15:33 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. today announced it has received Clinical Laboratory Improvement Amendments (CLIA) certification for a clinical test based on the LymphoSIGHT™ platform, marking a critical milestone for the clinical use of this next generation sequencing method for the monitoring of blood cancers. Sequenta expects to launch its first commercial test in 2013.